Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.

Slides:

Advertisements

Similar presentations

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Advertisements

Figure 3 Test reliability of enzymatic dissociation methods

Figure 5 Mononuclear cell subset isolation from spinal cord of mice with experimental autoimmune encephalomeylitis Mononuclear cell subset isolation from.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 JCV index changes in JCV+ patients

Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.

Figure 2 Comparative milestones in T and B lymphocyte maturation

Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 3 Gene expression in CSF cell pellets

Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Time points of blood sampling

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 2 Mononuclear cell numbers after enzymatic dissociation methods in mice with clinical experimental autoimmune encephalomyelitis Mononuclear cell.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 4 Pattern of relapse in patients with MOG-Ab Five myelin oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients experienced a relapse,

Figure 3 Analysis of the prognostic value of IL-10–producing B cells or IL-6/IL-10–B-cell ratio measurements in patients with RIS/CIS MS Analysis of the.

Figure 1 The human adaptive immune profile in multiple sclerosis (MS)‏

Figure 4 Aquaporin-4 immunoglobulin G (AQP4-IgG) index in time-matched paired serum-CSF specimens: 3 attack/preattack pairs and 7 bridge/remission pairs.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 2 Individual EDSS scores

Figure 4 Laquinimod treatment suppresses development of spontaneous EAE Laquinimod treatment suppresses development of spontaneous EAE (A) 2D2 × Th mice.

Figure 1 Phenotype and functional properties of B cells in MS and HCs at baseline Phenotype and functional properties of B cells in MS and HCs at baseline.

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.

Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Figure 1 Association between serum levels of IL-18 and hippocampal volume in patients with schizophrenia Scatter plots show a positive correlation between.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Figure 2 Spectrum of abnormal CT scanning of patients with bacterial meningitis presenting with a minimal Glasgow Coma Scale score Spectrum of abnormal.

Figure 2 Peripheral blood lymphocyte subset counts during dimethyl fumarate treatment(A) Lymphocyte subsets were obtained at baseline (n = 21) and at month.

Figure 1 Laquinimod treatment reduces the frequency of Tfh cells and IL-21–producing T cells in rMOG-induced EAE Laquinimod treatment reduces the frequency.

Figure 1 Examination of MuSK antibody levels and B-cell subsetsFlow cytometric analysis (n = 13) using standardized Human Immunology Project Consortium.

Figure 4 Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid.

Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis.

Figure 3 Laquinimod (LAQ) reduces microglia infiltration and acute axonal damage after 6 weeks of cuprizone Laquinimod (LAQ) reduces microglia infiltration.

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Figure 1 Distinct cognitive performers present differences in the cell populations of the adaptive immune systemThe profile (cell counts per mL of blood)

Figure 4 Increased susceptibility of MIF−/− CD4+ T cells to immunosuppression by Dex in EAE (A) MOG35-55 peptide-activated donor cells from wild-type (Wt)

Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy Evolution of blood cell counts during interleukin (IL)–7 therapy The leukocyte.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.

Figure 2 CD56bright natural killer (NK) cell counts in daclizumab high-yield process (DAC HYP)-treated patientsData are medians with 25th and 75th percentiles.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure Clinical course and overview of the treatment protocols♦ = neuroradiologic evidence of new disease activity; ★ = CD19+ reconstitution. Clinical.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Figure 3 Downregulation of T-bet expression in brain-infiltrating MIF−/− CD4+ T cells Macrophage migration inhibitory factor (MIF)−/− and wild-type (Wt)

Figure 2 B-cell very late antigen-4 (VLA-4) deficiency reduced CNS accumulation of B cells, but not proinflammatory or regulatory T cells (Treg), in myelin.

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Figure 2 Detection of atypical anti-neuronal antibodies Immunohistofluorescence assay on rat brain sagittal slices incubated with the patient's CSF and.

Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521

Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

Figure 2 Cell-based assay demonstrating differential binding of AChR antibodies to the adult and fetal receptorsThe fetal (gamma subunit specific) and.

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 1 EAE severity and CNS pathology in Dex-treated MIF−/− and Wt mice Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Figure 1 Tissue processing methods and cellular viability

Figure 2 Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Figure 1 Numbers/seropositivity rates of IVIg-naive and IVIg-exposed STRATIFY-2 enrollees* = % of enrollment samples, ** = date of IVIg and/or concentration.

Figure 4 Venn diagram for B-cell Sup proteins compared with proteins from exosome-enriched fractions from a human B-cell line Venn diagram for B-cell Sup.

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Figure 4 Longitudinal analysis of peripheral immune cell composition Frequency of naive, central memory (Tcm), and effector memory (Tem) CD4 T cells over.

Figure 1 Glutamine antagonist JHU083 inhibits T-cell proliferation in vitro Glutamine antagonist JHU083 inhibits T-cell proliferation in vitro T-cell proliferation.

Presentation transcript:

Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells (A) 2D2 × Th mice that had developed clinical signs of EAE (score ≥1) were randomly assigned to treatment with laquinimod (25 mg/kg) (n = 11) or vehicle (n = 11). Treatments were administered by oral gavage daily for 48 days. The frequency of Tfh cells (B), IL-21–producing Tfh cells (C), and germinal center B cells (E) were examined after 48 days of treatment. (D) Frequency of Tfh cells observed in lymph node and spleen cells isolated from naive mice treated with laquinimod or vehicle for 10 days. (F–G) Frequency of Treg cells (F) and IL-10–producing CD4+CD25+ T cells (G) detected in lymph node and spleen cells isolated from 2D2 × Th mice that had received laquinimod or vehicle treatment for 48 days. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Student t test. EAE = experimental autoimmune encephalomyelitis; Ig = immunoglobulin; IL = interleukin; LAQ = laquinimod; LN = lymph nodes; PD-1 = programmed cell death protein 1; Tfh = T follicular helper; Treg = T regulatory; Veh = vehicle. Michel Varrin-Doyer et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e272 © 2016 American Academy of Neurology